Picture loading failed.

Anti-IGF1&IGF2 therapeutic antibody (Pre-made Dusigitumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2.[1] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-160-1mg 1mg 3090
GMP-Bios-ab-160-10mg 10mg 21890
GMP-Bios-ab-160-100mg 100mg 148000
GMP-Bios-ab-160-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IGF1&IGF2 therapeutic antibody (Pre-made Dusigitumab biosimilar,Whole mAb)
INN Name Dusigitumab
TargetIGF1&IGF2
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesMedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Liver cancer;Solid tumours
Development Techna